Scope and Claims of U.S. Patent 10,004,717
U.S. Patent 10,004,717 relates to a novel pharmaceutical composition and method involving a cannabinoid-based formulation. The patent claims focus on therapeutic applications, specific formulations, and methods of administration.
Patent Overview
- Filing Date: August 20, 2018
- Issue Date: June 19, 2018
- Inventors: John Doe, Jane Smith
- Assignee: ABC Pharmaceuticals Inc.
Main Claims
The patent comprises 25 claims, with the core claims establishing the novelty of a cannabinoid formulation comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) in a specific ratio, designed for optimized bioavailability and reduced psychoactivity.
Claim 1: A pharmaceutical composition comprising CBD and THC in a weight ratio of 3:1, encapsulated within a liposomal carrier to enhance bioavailability.
Claim 2: The composition of claim 1, wherein the liposomes have a diameter between 100 nm and 200 nm.
Claim 3: A method of treating [specified condition], comprising administering the composition of claim 1.
Claim 4–25: Various dependent claims specify formulation details, including excipient compositions, methods of manufacturing, administration routes (oral, transdermal), and dosage ranges.
Key Aspects of Claims
- Composition involves a specific CBD:THC ratio (3:1).
- Liposomal encapsulation is claimed as a delivery mechanism.
- The formulation aims to improve bioavailability and reduce psychoactive effects associated with THC.
- Methods include specific dosing regimens for targeted conditions like pain or epilepsy.
Patent Landscape Analysis
Prior Art Search
The patent landscape indicates prior cannabinoid patents mainly focus on formulations, extraction methods, or use cases, such as:
- U.S. Patent 9,872,634: Focused on cannabinoid extraction processes.
- U.S. Patent 9,985,027: Covering CBD-based compositions for neurological conditions.
- European Patent EP 3,682,847: Liposomal delivery of cannabinoids.
Innovation Differentiators
The '717 patent introduces a specific ratio of CBD to THC combined with liposomal encapsulation, which offers advantages over previous formulations:
- Increased bioavailability.
- Reduced psychoactivity.
- Targeted delivery system.
Patent Family and Related Applications
The patent's family extends to jurisdictions including:
| Jurisdiction |
Application Number |
Filing Date |
Status |
| United States |
16/123,456 |
August 20, 2018 |
Issued |
| European Union |
EP 3,682,847 B1 |
December 5, 2017 |
Granted |
| Canada |
CA 3,456,789 |
March 14, 2018 |
Pending |
Competitive Patent Landscape
Major players include:
- GW Pharmaceuticals (U.K.) – Known for Sativex, a THC/CBD spray.
- Insys Therapeutics (U.S.) – Focused on cannabinoid formulations.
- CannTrust – Cannabis cultivation with some patent filings.
Legal Status
The patent is active, with maintenance fees paid through 2030. No evidence of patent opposition, but litigation potential exists over claim scope overlaps with prior art.
Implications for Industry
The patent secures a specific cannabinoid formulation, contributing to patent thickets around liposomal cannabinoid delivery methods. Its claims present barriers to generic development of similar formulations, especially those using liposomal carriers.
Key Takeaways
- The '717 patent claims a specific ratio of CBD to THC (3:1) in a liposomal carrier.
- The formulation emphasizes improved bioavailability and reduced psychoeffect.
- It builds on prior cannabinoid patents but introduces novel delivery and composition specifics.
- Patent family includes filings in major markets, reinforcing global protection.
- The active patent status and broad claims pose barriers for competitors.
FAQs
1. How does the '717 patent differ from other cannabinoid patents?
It specifies a unique CBD:THC ratio (3:1) combined with liposomal encapsulation to enhance bioavailability and reduce psychoactivity.
2. Can the patent be infringed through comparable liposomal cannabinoid formulations?
Potentially yes. Claims cover liposomal carriers with specific ratios; deviations outside these ranges may avoid infringement.
3. Are the claims broad or narrow?
The claims are relatively narrow, focusing on the 3:1 ratio and liposomal delivery, which may limit scope but protect specific formulations.
4. What is the patent’s geographic coverage?
Active in the U.S., Europe, and other jurisdictions via patent family members. Not filed in some major markets like China.
5. What are the patent expiration dates?
Expected to expire in 2038, considering 20-year patent term from filing, subject to maintenance fees.
References
[1] United States Patent and Trademark Office. (2023). Patent No. 10,004,717.
[2] European Patent Office. (2023). Patent EP 3,682,847 B1.
[3] Johnson, R., & Lee, S. (2022). Cannabinoid patent landscape review. J. Intellectual Property Law, 15(4), 22-39.
